An antibody therapy that targets red blood cells (RBCs) unexpectedly showed anti-inflammatory effects and rapidly reversed rheumatoid arthritis and prevented lung injury in mouse models. 

Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action to treat community-acquired bacterial pneumonia.

Zurich-based ADC maker Araris Biotech AG announced the closing of an oversubscribed seed financing round of CHF2.5m with Redalpine, Schroder Adveq and VI Partners contibuting.

Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.

Although it has only been shown to provide partial protection,  the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate one of the most deadly pathogens in human history?

The FDA has given the go-ahead to PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.

Manufacturers respond to stricter regulations with novel approaches.

Researchers at Karolinska Institutet have discovered a new sensory receptor organ that is able to detect painful mechanical damage, such as pricks and impacts.

British researchers have found out what’s going wrong with chromosome segregation in some cancers. 

Pharming NV has paid €17.9m upfront to Novartis AG for an exclusive license to CDZ173, a late stage drug for the treatment of APDS